Immunotherapy Positioning Marengo’s T cell activating platform offers a compelling entry point for pharma partners pursuing novel immunotherapy combinations. The invikafusp alfa story and the STAR program signal opportunities for licensing or co development with teams looking to expand into IO enhanced anti tumor strategies.

Clinical Momentum Active engagement at top oncology conferences and ongoing data readouts create external interest and validation, helping to open conversations with potential licensees or co development partners.

Leadership Credibility Having high profile leadership and a strong scientific advisory network increases deal credibility and can shorten path to collaboration by leveraging their industry connections.

Financial Flexibility Solid funding and revenue posture give Marengo the resources to advance collaborations quickly, while offering potential partners a lower risk path through financed development or milestone driven deals.

Targeted Market Fit Strategic focus on tissue rich and IO resistant cancers aligns with current market demand for novel immunotherapies, making IPN01203 STAR0501 a target for license or co development by companies seeking to augment their IO portfolios.